Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2021-08-16 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物2021年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2021 Half-Year Special Report on the Deposit and Use of Raised Funds" by a company. It details the status of funds raised through an IPO, their usage, balances, and compliance with regulatory requirements. The content focuses on the management and use of raised capital, including investment projects, cash management, and regulatory compliance. It is a specialized report on the use of fundraising proceeds for a half-year period, not a full annual report or a general interim financial report. The document is about the use of capital raised and its management, which aligns with a Capital/Financing Update (CAP) filing type rather than an Annual Report (10-K) or Interim Report (IR). The length (7195 characters) and detailed financial data support it being a substantive report rather than a mere announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-08-16 Chinese
前沿生物2021年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '2021 年半年度报告' which translates to '2021 Half-Year Report'. It contains detailed financial data, management discussion and analysis, company overview, financial indicators, and extensive information about the company's products and research pipeline. The document is comprehensive and includes actual financial statements and substantive financial data for the first half of 2021. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content and structure align with an Interim / Quarterly Report, which is a comprehensive financial report for a period shorter than a full fiscal year. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2021
2021-08-16 Chinese
前沿生物2021年限制性股票激励计划预留授予激励对象名单（截止授予日）
Remuneration Information Classification · 95% confidence The document is titled as a 2021 restricted stock incentive plan for a company, detailing the allocation of reserved shares to incentive recipients including directors, senior management, and other personnel. It includes specific numbers of shares granted and percentages relative to total share capital. The content focuses on share-based compensation and stock incentive plan details rather than financial results, management changes, or regulatory announcements. This type of document aligns with Remuneration Information filings, which report on compensation plans for executives and directors. The document length is short and contains detailed allocation data, not just an announcement or summary, so it is not a report publication announcement or regulatory filing. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2021-08-16 Chinese
前沿生物关于召开2021年半年度业绩说明会的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the scheduling and details of a 2021 half-year performance explanation meeting (业绩说明会) for investors. It mentions the date, time, location, and participation method for the meeting, as well as the fact that the company's 2021 half-year report has already been published on August 17, 2021. The document does not contain actual financial data or detailed financial analysis but serves to inform investors about the upcoming conference call or presentation to discuss the half-year results. This fits the definition of a Call Transcript (CT) or Investor Presentation (IP) only if the transcript or presentation content is included, which it is not. Instead, it is an announcement of the meeting itself. Given the short length (1396 characters) and the nature of the content, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the meeting and does not contain the actual report or transcript. It is not a Report Publication Announcement (RPA) because it does not announce the publication of the report but rather the meeting to discuss it. Therefore, the best classification is Regulatory Filings (RNS).
2021-08-16 Chinese
前沿生物监事会关于2021年限制性股票激励计划预留授予激励对象名单的核查意见（截止授予日）
Regulatory Filings Classification · 90% confidence The document is a supervisory board opinion on the verification of the reserved grant list of incentive objects under the 2021 restricted stock incentive plan. It references relevant laws and regulations regarding stock incentive plans and confirms the eligibility of the incentive recipients. The document is a formal opinion or report related to a stock incentive plan, not a full financial report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a regulatory announcement or a proxy solicitation. It is best classified under Regulatory Filings (RNS) as it is a compliance-related supervisory board opinion on stock incentive matters.
2021-08-16 Chinese
前沿生物独立董事关于第二届董事会第二十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters discussed at the company's board meeting, specifically regarding the half-year fundraising fund usage report and a restricted stock incentive plan. It references compliance with regulatory requirements and company bylaws, and provides an independent opinion on these matters. The document is short (1327 characters) and does not contain full financial statements or comprehensive financial data. It is not a full interim report or annual report but rather an opinion related to board/management decisions and governance matters. Therefore, it fits best under Board/Management Information (MANG).
2021-08-16 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.